Skip to content
akaturk Academic measurement

OpenAlex topic

Viral-associated cancers and disorders

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 2,334 works 27 author topics

Works

2,334 works

  1. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    Abstract We herein present an overview of the upcoming 5 th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we…

  2. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myelo…

  3. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.0%

    BACKGROUND: BK virus (BKV)-associated nephropathy (BKVAN) has been increasingly recognized as an important cause of renal transplant dysfunction. We report the role of quantitative viral load monitoring in the management of BKVAN. METHODS: We developed a real-time quantitative polymerase chain reaction (PCR) assay for…

  5. YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.1%

    Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate…

  6. YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.1%

    Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate…

  7. YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.1%

    Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate…

  8. YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.1%

    Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate…

  9. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.2%

    No abstract yet.

  10. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.2%

    No abstract yet.

  11. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.1%

    Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only ∼ 35%. Improvement in outcomes has been stymied by poor understanding of the genetics and molecular pathogenesis of PTCL, with a resulting paucity of molecular targets for therapy. We deve…

  12. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 97.2%

    Primary gastrointestinal (GI) T-cell lymphoma is an infrequent and aggressive disease. However, rare indolent clonal T-cell proliferations in the GI tract have been described. We report 10 cases of GI involvement by an indolent T-cell lymphoproliferative disease, including 6 men and 4 women with a median age of 48 yea…

Academicians

27 academicians